对商业上可用的SGLT2抑制剂及其结构-活性关系研究的洞察
Asiya Parveen1, Shazia Parveen2, Nisha Vats1
1Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.
Archiv der Pharmazie
|October 24, 2025
概括
-葡萄糖共载体2 (SGLT-2) 抑制剂为2型糖尿病的治疗提供了一种新的方法. 这些gliflozin通过防止脏的葡萄糖再吸收来降低血糖,解决了对更安全的抗糖尿病治疗的需求.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 2型糖尿病是一种日益严重的全球健康问题.
- 目前的抗高血糖药物有局限性,需要更安全,更有效的治疗方法.
- 胰岛素缺乏或耐药性是2型糖尿病的特征,这是一种需要持续管理的慢性疾病.
研究的目的:
- 审查-葡萄糖共载体2 (SGLT-2) 抑制剂作为2型糖尿病的新疗法.
- 探索gliflozins的特性,作用机制和治疗应用.
- 提供主要监管机构批准的SGLT-2抑制剂的概述.
主要方法:
- 文献综述侧重于SGLT-2抑制剂.
- 药物设计,开发和结构-活性关系的分析.
- 对监管部门的批准进行审查 (FDA,EMA,PMDA).
主要成果:
- SGLT-2 抑制剂在治疗2型糖尿病方面取得了重大进展.
- 这些药物通过抑制脏中的葡萄糖再吸收来降低血糖.
- 经批准的gliflozins证明了有效性,并为现有疗法提供了替代方案.
结论:
- SGLT-2 抑制剂是抗糖尿病治疗武器库中宝贵的补充.
- 它们独特的机制提供了超出血糖控制的潜在好处.
- 对它们的治疗应用和长期影响进行进一步的研究是有必要的.
相关概念视频
Glucose Transporters
27.2K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.2K
Structure-Activity Relationships and Drug Design
1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
Glucagon-like Receptor Agonists
840
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
840
Dipeptidyl Peptidase 4 Inhibitors
581
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
581
Ligand Binding and Linkage
5.5K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.5K
Oral Hypoglycemic Agents: Glinides
595
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
595


